WO2021166986A1 - 貼付製剤 - Google Patents
貼付製剤 Download PDFInfo
- Publication number
- WO2021166986A1 WO2021166986A1 PCT/JP2021/006051 JP2021006051W WO2021166986A1 WO 2021166986 A1 WO2021166986 A1 WO 2021166986A1 JP 2021006051 W JP2021006051 W JP 2021006051W WO 2021166986 A1 WO2021166986 A1 WO 2021166986A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- propylene glycol
- drug
- fatty acid
- adhesive layer
- patch
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 105
- 239000003814 drug Substances 0.000 claims abstract description 76
- 229940079593 drug Drugs 0.000 claims abstract description 73
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims abstract description 68
- -1 propylene glycol fatty acid ester Chemical class 0.000 claims abstract description 65
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 45
- 229930195729 fatty acid Natural products 0.000 claims abstract description 45
- 239000000194 fatty acid Substances 0.000 claims abstract description 45
- 229940040102 levulinic acid Drugs 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000012790 adhesive layer Substances 0.000 claims abstract description 13
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims abstract description 5
- 229950000505 tandospirone Drugs 0.000 claims abstract description 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 67
- 239000010410 layer Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 37
- 238000009472 formulation Methods 0.000 claims description 34
- 229920000058 polyacrylate Polymers 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 150000002148 esters Chemical group 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 10
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 10
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 5
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 26
- 231100000245 skin permeability Toxicity 0.000 abstract description 16
- 210000003491 skin Anatomy 0.000 description 26
- 239000000178 monomer Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 239000002585 base Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000853 adhesive Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000123 paper Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 9
- 239000004745 nonwoven fabric Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 229920002554 vinyl polymer Polymers 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- UUORTJUPDJJXST-UHFFFAOYSA-N n-(2-hydroxyethyl)prop-2-enamide Chemical compound OCCNC(=O)C=C UUORTJUPDJJXST-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002985 plastic film Substances 0.000 description 3
- 229920006255 plastic film Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 239000013032 Hydrocarbon resin Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000004637 bakelite Substances 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229920006270 hydrocarbon resin Polymers 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KZNPIUNERUJTFX-UHFFFAOYSA-N n-(2-hydroxybutyl)prop-2-enamide Chemical compound CCC(O)CNC(=O)C=C KZNPIUNERUJTFX-UHFFFAOYSA-N 0.000 description 2
- BSCJIBOZTKGXQP-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCO BSCJIBOZTKGXQP-UHFFFAOYSA-N 0.000 description 2
- YXMYPOYILIWOID-UHFFFAOYSA-N n-(3-hydroxybutyl)prop-2-enamide Chemical compound CC(O)CCNC(=O)C=C YXMYPOYILIWOID-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OUPZKGBUJRBPGC-UHFFFAOYSA-N 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(CC2OC2)C(=O)N(CC2OC2)C(=O)N1CC1CO1 OUPZKGBUJRBPGC-UHFFFAOYSA-N 0.000 description 1
- PBGPBHYPCGDFEZ-UHFFFAOYSA-N 1-ethenylpiperidin-2-one Chemical compound C=CN1CCCCC1=O PBGPBHYPCGDFEZ-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- WPIOBXGJZUSKGK-UHFFFAOYSA-N 16-methylheptadecyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C WPIOBXGJZUSKGK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- JPWUIQIFCDAWQX-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(O)CO JPWUIQIFCDAWQX-UHFFFAOYSA-N 0.000 description 1
- OATHWIHWTWDNLJ-UHFFFAOYSA-N 2-(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCCCCCC(C)C OATHWIHWTWDNLJ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- ZVTDEEBSWIQAFJ-KHPPLWFESA-N 2-hydroxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-KHPPLWFESA-N 0.000 description 1
- JEMDXOYRWHZUCG-UHFFFAOYSA-N 2-octadecanoyloxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCCCCCCCC JEMDXOYRWHZUCG-UHFFFAOYSA-N 0.000 description 1
- GAVHQOUUSHBDAA-UHFFFAOYSA-N 3-butyl-1-ethenylaziridin-2-one Chemical compound CCCCC1N(C=C)C1=O GAVHQOUUSHBDAA-UHFFFAOYSA-N 0.000 description 1
- ZMALNMQOXQXZRO-UHFFFAOYSA-N 4-ethenylmorpholin-3-one Chemical compound C=CN1CCOCC1=O ZMALNMQOXQXZRO-UHFFFAOYSA-N 0.000 description 1
- HDYTUPZMASQMOH-UHFFFAOYSA-N 4-ethenylmorpholine-3,5-dione Chemical compound C=CN1C(=O)COCC1=O HDYTUPZMASQMOH-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- MQQXUGFEQSCYIA-OAWHIZORSA-M aluminum;(z)-4-ethoxy-4-oxobut-2-en-2-olate;propan-2-olate Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CCOC(=O)\C=C(\C)[O-] MQQXUGFEQSCYIA-OAWHIZORSA-M 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005442 diisocyanate group Chemical class 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- NYMPGSQKHIOWIO-UHFFFAOYSA-N hydroxy(diphenyl)silicon Chemical class C=1C=CC=CC=1[Si](O)C1=CC=CC=C1 NYMPGSQKHIOWIO-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KRSOEVAVUOYJDA-UHFFFAOYSA-N n-(1-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CCC(O)NC(=O)C(C)=C KRSOEVAVUOYJDA-UHFFFAOYSA-N 0.000 description 1
- AADPGYDUTSGSMI-UHFFFAOYSA-N n-(1-hydroxypropyl)prop-2-enamide Chemical compound CCC(O)NC(=O)C=C AADPGYDUTSGSMI-UHFFFAOYSA-N 0.000 description 1
- IPGRTXQKFZCLJS-UHFFFAOYSA-N n-(2-hydroxypropyl)prop-2-enamide Chemical compound CC(O)CNC(=O)C=C IPGRTXQKFZCLJS-UHFFFAOYSA-N 0.000 description 1
- ZTUGCJNAJJDKDC-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCO ZTUGCJNAJJDKDC-UHFFFAOYSA-N 0.000 description 1
- ZEMHQYNMVKDBFJ-UHFFFAOYSA-N n-(3-hydroxypropyl)prop-2-enamide Chemical compound OCCCNC(=O)C=C ZEMHQYNMVKDBFJ-UHFFFAOYSA-N 0.000 description 1
- TVDRFWWLJYRVMV-UHFFFAOYSA-N n-(4-hydroxybutyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCCO TVDRFWWLJYRVMV-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920003251 poly(α-methylstyrene) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010558 suspension polymerization method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Definitions
- the present invention relates to a patch containing a drug, levulinic acid, and a propylene glycol fatty acid ester.
- Percutaneous absorption preparations such as patch preparations are not only aimed at treating lesions on the skin surface or tissues directly under the skin application site by local drug absorption, but also the drug that has penetrated the skin is further subcutaneously micronized. It is used as a preparation that is expected to act on the whole body by being taken directly into blood vessels.
- Transdermal administration of the drug with such a patch or the like can avoid the first pass effect in the liver, so that overdose of the drug can be suppressed, and when the transdermal administration of the drug is interrupted, By peeling the patch from the applied skin surface, it has the advantage that the administration of the drug can be easily and safely interrupted.
- the skin to which the patch is applied has a barrier function to prevent foreign substances from entering from the outside, in many cases, a necessary and sufficient amount of the drug is used to exert the medicinal effect of the drug. Is difficult to penetrate through the skin. Therefore, conventionally, various measures have been taken to improve the transdermal permeability of the drug.
- Patent Document 1 it is conceivable to improve the skin permeability of the drug by increasing the plane area of the patched product, but the problem of handleability due to the large plane area (difficult to stick to the skin, difficult to replace, etc.) , There is a problem that stuffiness and itching sensation are likely to occur during application to the skin (Patent Document 1). Attempts have also been made to improve the skin permeability of drugs by including a transdermal absorption promoter in the patch formulation, but it may be difficult to obtain sufficient skin permeability depending on the drug. Alternatively, depending on the type of the transdermal absorption promoter, adverse effects such as a decrease in the adhesive property (cohesive force, etc.) of the patch may occur (Patent Document 2).
- an object of the present invention is to provide a patch preparation having excellent skin permeability of a drug and good adhesive properties.
- the present inventors have applied a drug (excluding tandospirone or a pharmaceutically acceptable salt thereof), levulinic acid, to the pressure-sensitive adhesive layer in the patch formulation.
- a drug excluding tandospirone or a pharmaceutically acceptable salt thereof
- levulinic acid levulinic acid
- propylene glycol fatty acid ester it has been found that practical adhesive properties and drug skin permeability as a transdermal preparation can be imparted, and skin irritation at the time of peeling can be reduced.
- the present invention has been completed.
- the present invention is as follows.
- the patch layer is characterized by containing a drug (excluding tandospirone or a pharmaceutically acceptable salt thereof), levulinic acid, and a propylene glycol fatty acid ester (hereinafter, "the patch of the present invention”). It may also be referred to as “formulation”).
- the patch preparation according to the above [1] wherein the propylene glycol fatty acid ester is an ester of propylene glycol and a saturated or unsaturated fatty acid having 8 to 18 carbon atoms.
- [6] The patch according to any one of [1] to [5] above, wherein the content of the propylene glycol fatty acid ester in 100% by mass of the pressure-sensitive adhesive layer is 1 to 30% by mass.
- [7] The patch according to any one of the above [1] to [6], wherein the content ratio of levulinic acid and propylene glycol fatty acid ester is 1: 0.1 to 1:20 in terms of mass ratio.
- a patch preparation having excellent skin permeability of a drug and good adhesive properties (cohesive force, water-resistant adhesiveness, etc.).
- FIG. 1A and 1B are views showing a measurement method of an underwater constant load peeling test of a patched product
- FIG. 1A is a schematic perspective view thereof
- FIG. 1B is a schematic front view thereof. Note that each dimension and dimensional ratio in the figure are exaggerated for convenience of explanation and may differ from the actual ratio.
- Adhesive layer The patch of the present invention is characterized by containing a drug, levulinic acid, and a propylene glycol fatty acid ester in the adhesive layer.
- the drug in the patch of the present invention may be a drug that can be administered to a mammal such as a human through its skin (that is, a drug that can be transdermally absorbed), except that tandospirone or a pharmaceutically acceptable salt thereof is removed.
- a mammal such as a human through its skin
- drugs include, for example, systemic anesthetics, hypnotics / sedatives, antitussives, antipyretic analgesics, antitussives, vasodilators, neuropsychiatric drugs, central nervous system drugs, anti-dementia drugs, local anesthetics, skeletal muscles.
- the drug may be in the form of a free base or in the form of a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salt is not particularly limited, but is, for example, formate, acetate, lactate, adipate, citrate, tartrate, methanesulfonate (also called mesylate), benzene.
- Addition salts of organic acids such as sulfonates (also called besilates), fumarates, maleates; addition salts of inorganic acids such as hydrochlorides, sulfates, nitrates, phosphates; meglumine salts, piperazine salts ,
- Addition salts of organic bases such as tromethamine salt, choline salt, diethylamine salt, tert-butylamine salt; addition salts of inorganic bases such as sodium salt, calcium salt, potassium salt, magnesium salt, aluminum salt, ammonium salt; etc. Be done.
- the drug may be a solvate (for example, a hydrate, an ethanol solvate, a propylene glycol solvate) or a non-solvate.
- a basic drug having a basic group As the drug in the patch preparation of the present invention, it is preferable to use a basic drug having a basic group.
- drugs include, for example, alcoholic hydroxy groups, sulfanyl groups, phenolic hydroxy groups, and amino groups (eg, primary amino group (-NH 2 ), secondary amino group (-NRH), first. Select from the group consisting of a tertiary amino group (-NRR'); where R and R'independently represent an optionally substituted alkyl group or an optionally substituted aryl group). Examples thereof include drugs having at least one functional group to be treated.
- the partition coefficient of the drug (1-octanol / water) in the patch formulation of the present invention is preferably -1, more preferably 0, still more preferably 1, and the upper limit of logPow is preferable. Is 7, more preferably 6, and even more preferably 5.
- the logpower of the drug is in the range of -1 to 7, the drug dispersibility in the pressure-sensitive adhesive layer is excellent.
- logPower is an index showing the hydrophilicity or hydrophobicity of a drug, and is "OECD GUIDELINE FOR THE TESTING OF CHEMICALS 107, Applied by the Council on 27th July 1995, Partition Coefficient (n-octanol / water), Shake.
- the value measured for each drug by the method described in "Flask Method”, and the logarithmic base of logPow is 10.
- logPow was calculated using logP calculation software (manufactured by Scigress Fujitsu Limited).
- the structural formula of the compound is input to the calculation software to calculate logPower.
- the content of the drug in the pressure-sensitive adhesive layer is not particularly limited as long as the effect of the drug is exhibited and side effects do not occur, but the lower limit of the content of the drug is preferably 100% by mass of the pressure-sensitive adhesive layer. , 0.1% by mass, more preferably 0.5% by mass, still more preferably 1% by mass.
- the upper limit of the drug content is preferably 50% by mass, more preferably 40% by mass, and further preferably 30% by mass in 100% by mass of the pressure-sensitive adhesive layer. If the content of the drug is less than 0.1% by mass, sufficient drug efficacy may not be obtained, and conversely, if the content of the drug exceeds 50% by mass, side effects caused by the drug (for example, during application). Skin irritation, etc.) may occur.
- the levulinic acid used in the present invention is an organic acid classified as keto acid.
- Levulinic acid may be in the form of a free acid (ie, levulinic acid itself) or in the form of a pharmaceutically acceptable salt thereof.
- the pharmaceutically acceptable salt include alkali metal salts such as sodium salt and the like.
- a commercially available product may be used as it is, or a pharmaceutically acceptable salt thereof prepared from levulinic acid according to a method known per se may be used.
- levulinic acid used in the present invention levulinic acid, which is a free acid, is preferable.
- the content of levulinic acid in the pressure-sensitive adhesive layer is not particularly limited, but the upper limit of the content of levulinic acid is preferably 30% by mass, more preferably 20% by mass, based on 100% by mass of the pressure-sensitive adhesive layer. It is more preferably 15% by mass.
- the lower limit of the content of levulinic acid is preferably 0.1% by mass, more preferably 0.5% by mass, and further preferably 1% by mass in 100% by mass of the pressure-sensitive adhesive layer. When the content of levulinic acid in the pressure-sensitive adhesive layer is less than 0.1% by mass, it becomes difficult to obtain necessary and sufficient skin permeability of the drug.
- the content of levulinic acid in the pressure-sensitive adhesive layer exceeds 30% by mass, the shape-retaining property of the pressure-sensitive adhesive layer is lowered, and glue squeezes out during storage of the patch-coated product, or after application of the patch-coated product, When the patch is peeled off from the skin surface, adhesive residue may be left on the skin surface.
- the propylene glycol fatty acid ester used in the present invention is an ester of propylene glycol and a saturated or unsaturated fatty acid having 8 to 18 carbon atoms, and examples thereof include propylene glycol monofatty acid ester and propylene glycol difatty acid ester. Be done.
- Specific examples of the propylene glycol fatty acid ester include, for example, propylene glycol monocaprelate, propylene glycol monocaplate, propylene glycol monolaurate, propylene glycol monostearate, propylene glycol monooleate, propylene glycol dicaprelate, and propylene glycol dicaplate.
- Propylene Glycol Dicaprylate / Dica Plate (Propylene Glycol Dicapryloca Plate), Propylene Glycol Dilaurate, Propylene Glycol Distearate, Propylene Glycol Diisostearate, Propylene Glycol Diolate, etc.
- Esterates with saturated or unsaturated fatty acids having 8 to 14 carbon atoms are preferable, and propylene glycol monocaprelate or propylene glycol monolaurate is more preferable.
- These propylene glycol fatty acid esters can be used alone or in combination of two or more.
- the content of the propylene glycol fatty acid ester in the pressure-sensitive adhesive layer is not particularly limited, but the upper limit of the content of the propylene glycol fatty acid ester is preferably 30% by mass, more preferably 30% by mass, based on 100% by mass of the pressure-sensitive adhesive layer. , 25% by mass, more preferably 20% by mass.
- the lower limit of the content of the propylene glycol fatty acid ester is preferably 1% by mass, more preferably 2% by mass, and further preferably 3% by mass in 100% by mass of the pressure-sensitive adhesive layer.
- the content ratio of levulinic acid and propylene glycol fatty acid ester (levulinic acid: propylene glycol fatty acid ester) in the pressure-sensitive adhesive layer is preferably 1: 0.1 to 1:20 in terms of mass ratio, which is more preferable. Is in the range of 1: 0.2 to 1:15, more preferably 1: 0.3 to 1:10, and particularly preferably 1: 0.5 to 1:10.
- the content of propylene glycol fatty acid ester in the pressure-sensitive adhesive layer and the content ratio of levulinic acid and propylene glycol fatty acid ester are out of the above ranges, good drug skin permeability and practical adhesive properties (cohesion) It becomes difficult to achieve both strength and water resistance (adhesion resistance, etc.).
- the pressure-sensitive adhesive layer further contains a fatty acid ester other than the propylene glycol fatty acid ester.
- fatty acid esters include fatty acid alkyl esters such as ethyl laurate, isostearyl laurate, isopropyl myristate, isotridecyl myristate, isopropyl palmitate, octyl palmitate, and ethyl oleate (having 1 carbon number).
- the content of other fatty acid esters in the pressure-sensitive adhesive layer is not particularly limited, but the upper limit of the content of other fatty acid esters is preferably 85% by mass, more preferably 85% by mass, based on 100% by mass of the pressure-sensitive adhesive layer. , 80% by mass, more preferably 75% by mass.
- the lower limit of the content of the other fatty acid ester is preferably 5% by mass, more preferably 7.5% by mass, and further preferably 10% by mass in 100% by mass of the pressure-sensitive adhesive layer.
- a pressure-sensitive adhesive layer containing a non-water-containing pressure-sensitive adhesive base is preferable in order to exhibit good skin adhesiveness.
- a non-moisture-containing pressure-sensitive adhesive layer is not limited to a layer that does not completely contain water, and a small amount of water (for example, in the pressure-sensitive adhesive layer) derived from water in the air or skin or the like. Those containing (less than 1% by mass) are included.
- the pressure-sensitive adhesive base means a polymer that constitutes a matrix of the pressure-sensitive adhesive layer.
- the pressure-sensitive adhesive is, if necessary, blended with a tack fire (adhesive-imparting agent) described later to form a pressure-sensitive adhesive.
- Only one type of adhesive base may be used, or two or more types may be used in combination.
- Examples of the non-hydrous adhesive base include acrylic polymers such as (meth) acrylic acid ester-based polymers; styrene-isoprene-styrene block copolymers, styrene-butadiene-styrene block copolymers, polyisoprenes, and polys.
- Rubber-based polymers such as isobutylene and polybutadiene; silicone-based polymers such as silicone rubber, dimethylsiloxane base, and diphenylsiloxane base can be mentioned.
- an acrylic polymer is contained because it is easy to adjust the release property of the drug and the adhesive force, and it is less irritating to the skin. Is preferable.
- the acrylic polymer is not particularly limited, but for example, an acrylic polymer obtained from a monomer mixture containing a (meth) acrylic acid alkyl ester monomer is preferably used.
- (meth) acrylic means both "acrylic" and "methacryl”.
- the (meth) acrylic acid alkyl ester monomer (hereinafter, also referred to as “first monomer”) is not particularly limited, but has an alkyl group having 4 or more carbon atoms from the viewpoint of adhesiveness.
- a (meth) acrylic acid alkyl ester monomer is preferable.
- Examples of the (meth) acrylic acid alkyl ester monomer include an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, and a hexyl group.
- Heptyl group, octyl group, 2-ethylhexyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group and the like are linear alkyl groups or branched alkyl groups having 4 to 13 carbon atoms (meth).
- Acrylic acid alkyl ester monomer can be mentioned. Among them, butyl (meth) acrylate and 2-ethylhexyl (meth) acrylate are preferable, and 2-ethylhexyl acrylate is particularly preferable.
- These (meth) acrylic acid alkyl ester monomers can be used alone or in combination of two or more.
- N-vinyl cyclic amide (hereinafter, also referred to as “second monomer”) in addition to the (meth) acrylic acid alkyl ester monomer.
- Acrylic polymers obtained by copolymerizing the body mixture are preferable.
- N-vinyl cyclic amides include N-vinyl-2-pyrrolidone, N-vinyl-2-piperidone, N-vinyl-3-morpholinone, N-vinyl-2-caprolactam, and N-vinyl-1. , 3-Oxazine-2-one, N-vinyl-3,5-morpholindione and the like. Of these, N-vinyl-2-pyrrolidone is particularly preferable.
- These N-vinyl cyclic amides can be used alone or in combination of two or more.
- N-vinyl cyclic amide When N-vinyl cyclic amide is contained as a monomer component constituting the acrylic polymer, the content thereof is preferably 75% by mass or less, more preferably 1 to 75% in the acrylic polymer. It is by mass, more preferably 5 to 75% by mass, particularly preferably 10 to 70% by mass, and most preferably 15 to 65% by mass.
- the adhesive force and cohesive force of the patch By copolymerizing N-vinyl cyclic amide, the adhesive force and cohesive force of the patch can be adjusted, and the solubility of the drug in the adhesive layer and the release property of the drug from the adhesive layer can be adjusted. can do. If the content of N-vinyl cyclic amide in the acrylic polymer exceeds 75% by mass, the tackiness and adhesive strength of the obtained patch may decrease.
- a monomer component constituting the acrylic polymer a monomer mixture containing a monomer having another functional group (hereinafter, also referred to as “third monomer”) is copolymerized. It may be an acrylic polymer.
- examples of such other functional groups include a carboxyl group, a hydroxy group, a vinyl group and the like, and among them, a carboxyl group and a hydroxy group are preferable.
- Specific examples of monomers having other functional groups include (meth) acrylic acid, itaconic acid, (anhydrous) maleic acid, mesaconic acid, citraconic acid, glutaconic acid, and (meth) acrylic acid hydroxyethyl ester.
- N-hydroxyalkyl (meth) acrylamide examples thereof include (meth) acrylic acid hydroxypropyl ester and N-hydroxyalkyl (meth) acrylamide.
- the N-hydroxyalkyl (meth) acrylamide is preferably N-hydroxyalkyl (C1-4) (meth) acrylamide having 1 to 4 carbon atoms in the alkyl group, and more preferably the carbon number of the alkyl group. Is N-hydroxyalkyl (C2-4) acrylamide, which is 2-4.
- the alkyl group in the hydroxyalkyl group may be linear or branched.
- N-hydroxyalkyl (meth) acrylamide examples include N- (2-hydroxyethyl) acrylamide, N- (2-hydroxyethyl) methacrylamide, N- (2-hydroxypropyl) acrylamide, and N-(.
- 2-Hydroxypropyl) methacrylamide N- (1-hydroxypropyl) acrylamide, N- (1-hydroxypropyl) methacrylamide, N- (3-hydroxypropyl) acrylamide, N- (3-hydroxypropyl) methacrylicamide, N- (2-Hydroxybutyl) Acrylamide, N- (2-Hydroxybutyl) Acrylamide, N- (3-Hydroxybutyl) Acrylamide, N- (3-Hydroxybutyl) Acrylamide, N- (4-Hydroxybutyl) Examples thereof include acrylamide and N- (4-hydroxybutyl) methacrylicamide.
- acrylic acid, methacrylic acid, acrylate hydroxyethyl ester, N- (2-hydroxyethyl) acrylamide, N- (2-hydroxyethyl) methacrylicamide are preferable, and acrylic acid, Acrylic acid hydroxyethyl ester and N- (2-hydroxyethyl) acrylamide are more preferable.
- acrylic acid, methacrylic acid, acrylate hydroxyethyl ester, N- (2-hydroxyethyl) acrylamide, N- (2-hydroxyethyl) methacrylicamide are preferable, and acrylic acid, Acrylic acid hydroxyethyl ester and N- (2-hydroxyethyl) acrylamide are more preferable.
- These other monomers having functional groups can be used alone or in combination of two or more.
- the acrylic polymer is a (meth) acrylic acid alkyl ester (first monomer), an N-vinyl cyclic amide (second monomer), and a monomer having other functional groups (third monomer). ),
- the copolymerization ratio (first monomer / second monomer / third monomer) is 20 to 90% by mass / 5 to 75% by mass / 1 to 15.
- the mass% is preferable, 25 to 85% by mass / 10 to 70% by mass / 1 to 10% by mass is more preferable, and 30 to 80% by mass / 15 to 65% by mass / 1 to 10% by mass is particularly preferable.
- the acrylic polymer can be obtained by a known polymerization method such as a solution polymerization method, an emulsion polymerization method, or a suspension polymerization method. It can also be obtained by performing radical polymerization using a radical polymerization initiator such as a peroxide compound (for example, benzoyl peroxide) or an azo compound (for example, azobisisobutyronitrile). ..
- a radical polymerization initiator such as a peroxide compound (for example, benzoyl peroxide) or an azo compound (for example, azobisisobutyronitrile).
- a tack fire (adhesive imparting agent) may be further added in order to impart adhesiveness at room temperature to the adhesive layer.
- a tack fire may be further blended in order to enhance the adhesiveness of the pressure-sensitive adhesive layer.
- the tack fire those known in the field of the patch formulation can be appropriately selected and used.
- tack fire examples include petroleum-based resins (for example, aromatic petroleum resins, aliphatic petroleum resins, etc.), terpene-based resins, rosin-based resins, kumaron inden resins, and styrene-based resins (for example, styrene).
- petroleum-based resins for example, aromatic petroleum resins, aliphatic petroleum resins, etc.
- terpene-based resins for example, rosin-based resins, kumaron inden resins
- styrene-based resins for example, styrene
- examples thereof include resins, poly ( ⁇ -methylstyrene) and the like), hydrogenated petroleum resins (for example, alicyclic saturated hydrocarbon resins and the like) and the like.
- an alicyclic saturated hydrocarbon resin is preferable because the storage stability of the drug is improved.
- its content in the pressure-sensitive adhesive layer is usually 30 parts by mass or more and less than 100 parts by mass, preferably 50 parts by mass or more and 100 parts by mass with respect to 100 parts by mass of the pressure-sensitive adhesive base. Less than a copy.
- a cross-linking treatment can be performed as necessary in order to impart an appropriate cohesive force to the pressure-sensitive adhesive layer.
- the cross-linking treatment includes physical cross-linking treatment (for example, cross-linking treatment by ⁇ -ray irradiation, electron beam irradiation, etc.) and chemical cross-linking treatment (for example, organic peroxide, isocyanate compound, organic metal salt, metal alcoholate, metal).
- Cross-linking treatment with a cross-linking agent such as a chelate compound, an epoxy compound, or a primary amino group-containing compound
- the chemical cross-linking treatment include organic peroxides such as benzoyl peroxide, isocyanate compounds such as tolylene diisocyanate and hexamotylene diisocyanate, and epoxy compounds such as glycerin triglycidyl ether and triglycidyl isocyanurate. , Aluminum tris (acetylacetonate), aluminum ethylacetacetate diisopropirate and other metal chelating compounds and the like.
- the amount of the cross-linking agent to be blended can be appropriately adjusted depending on the type of the pressure-sensitive adhesive base and the cross-linking agent, but is preferably 0.03 to 2. It is 0 parts by mass, more preferably 0.05 to 1.5 parts by mass, and even more preferably 0.07 to 1.0 parts by mass.
- the pressure-sensitive adhesive layer in the patched product of the present invention may contain a fragrance, a colorant, a plasticizer, a softening agent, a filler, a stabilizer, an antioxidant, and an antibacterial agent, as necessary, as long as the effects of the present invention are not impaired.
- Various additives such as an agent and a bactericide may be appropriately blended.
- the additive those known in the field of the patch formulation can be appropriately selected and used.
- the upper limit of the thickness of the pressure-sensitive adhesive layer is preferably 500 ⁇ m, more preferably 400 ⁇ m, and even more preferably 300 ⁇ m.
- the lower limit of the thickness of the pressure-sensitive adhesive layer is preferably 10 ⁇ m, more preferably 20 ⁇ m, and even more preferably 30 ⁇ m.
- the support constituting the patched product of the present invention is not particularly limited as long as it can form and hold the pressure-sensitive adhesive layer on one side.
- the material of the support include polyester (for example, polyethylene terephthalate (PET), etc.), polyamide (for example, nylon, etc.), polyethylene, polypropylene, polyvinyl chloride, polyvinylidene chloride (trade name: Saran, etc.), and ionomer resin. (Product name: Sarlin, etc.), polytetrafluoroethylene, ethylene-ethyl acrylate copolymer, ethylene-vinyl alcohol copolymer (trade name: EVAL, etc.), various metals and the like can be mentioned.
- the support may be a single layer of various plastic films or various metal foils made of the above materials, or a laminate thereof. Further, in order to improve the anchoring property with the pressure-sensitive adhesive layer formed on the support, the surface of the support can be treated with an undercoat layer, a corona discharge treatment, a plasma irradiation treatment, a primer treatment and the like.
- a laminated body in which a porous sheet is laminated on the pressure-sensitive adhesive layer forming side of the support can be used.
- a perforated sheet include aggregates of fibers such as paper, knitted fabric, woven fabric, and non-woven fabric (for example, polyester non-woven fabric, polyethylene terephthalate non-woven fabric, etc.), and simple materials such as the plastic film.
- examples thereof include a layered body (single layer film) and a sheet obtained by mechanically perforating a laminated film obtained by laminating one or more of these films, among which paper, woven fabric, and non-woven fabric (for example, polyester).
- Non-woven fabric, polyethylene terephthalate non-woven fabric, etc. are preferable.
- the thickness of the support is preferably 10 to 200 ⁇ m, more preferably 10 to 100 ⁇ m, from the viewpoint of improving anchoring property, flexibility of the patched formulation, sticking operability, and the like.
- the basis weight of these is preferably 5 to 30 g / m 2 , and more preferably 6 to 15 g / m 2 .
- the release liner is laminated on the surface of the pressure-sensitive adhesive layer opposite to the support side (the surface to be attached to the skin) until the formulation is actually used. ..
- the release liner is not particularly limited as long as it has good release property at the time of use.
- plastic films such as polyester, polyvinyl chloride, polyvinylidene chloride, and polyethylene terephthalate, which have been peeled off by applying a silicone resin, fluororesin, or the like to the surface in contact with the pressure-sensitive adhesive layer, and high-quality paper.
- Paper such as glassin paper, high-quality paper, laminated film of paper such as glassin paper and polyolefin (paper on the side in contact with the adhesive layer) and the like.
- the thickness (overall thickness) of the release liner is not particularly limited, but is preferably 10 to 200 ⁇ m, more preferably 25 to 100 ⁇ m.
- the size of the patch formulation of the present invention is not particularly limited, but is usually 1 to 300 cm 2 , preferably 2 to 200 cm 2 , and more preferably 3 to 100 cm 2 .
- the patch formulation of the present invention is usually 3 times / day to 1 time / 2 weeks, preferably 2 times / day to 1 time / week, more preferably 1 time / day to 1 time / week, and more preferably. It is replaced once / day to once / four days.
- the present invention of the patch preparation of the present invention can be manufactured by the following manufacturing method.
- Adhesive base containing acrylic polymer, drug, levulinic acid and propylene glycol fatty acid ester are added to a suitable solvent together with other additives as necessary, and mixed thoroughly until uniform.
- the solvent include ethyl acetate, toluene, hexane, 2-propanol, methanol, ethanol, water and the like. Then, when a cross-linking agent is blended, the cross-linking agent is further added to this mixed solution and mixed sufficiently. At this time, if necessary, a solvent may be added together with the cross-linking agent and mixed.
- the obtained mixed solution is applied to one side of the support or the peeled surface of the peeling liner and dried to form an adhesive layer.
- the coating can be carried out by, for example, casting, printing, or other techniques known to those skilled in the art.
- a release liner or a support is attached to the pressure-sensitive adhesive layer to form a laminated body.
- the cross-linking reaction is promoted by leaving it at room temperature to 120 ° C., preferably room temperature to 100 ° C. for 8 to 48 hours. To form a crosslinked pressure-sensitive adhesive layer.
- the formed adhesive layer was bonded to the non-woven fabric side of a support which is a laminated film of a polyester film having a thickness of 2 ⁇ m and a polyester non-woven fabric (grain size: 12 g / m 2) to obtain a patched formulation.
- the content (mass%) of each component as a patch formulation is as shown in Tables 4 and 5.
- a test plate was prepared by attaching a collagen film 22 (width 25 mm, length 100 mm, thickness 38 ⁇ m) to a bakelite plate 23 (width 30 mm, length 130 mm, thickness 2 mm) via double-sided tape (not shown). Next, the patch 21 is cut into a rectangular shape having a width of 10 mm and a length of 40 mm, and the release paper is peeled off to expose the pressure-sensitive adhesive layer surface. A test sample was obtained by pressure-bonding and adhering one round trip. In this state, after 10 minutes have passed at room temperature, a support 27 having the shape shown in FIG.
- Tables 6 and 7 show the results of the skin permeability test 2, the cohesive force test, and the underwater constant load peeling test.
- the patch containing levulinic acid and PGML includes a patch containing levulinic acid but not PGML (Comparative Example 6 and Comparative Example 18) and a patch containing PGML.
- the patch preparations containing levulinic acid and PGMC include a patch preparation containing levulinic acid but not PGMC (Comparative Example 13 and Comparative Example 24) and PGMC.
- the present invention by containing a drug, levulinic acid, and a propylene glycol fatty acid ester in the pressure-sensitive adhesive layer, it has good adhesive properties (cohesive force, water-resistant adhesiveness) and makes the drug skin permeable.
- An excellent patch formulation can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1]支持体の少なくとも片面に粘着剤層を有する貼付製剤であって、
該粘着剤層が、薬物(但し、タンドスピロン又はその薬学的に許容される塩を除く)、レブリン酸、及びプロピレングリコール脂肪酸エステルを含有することを特徴とする貼付製剤(以下、「本発明の貼付製剤」と称することもある。)。
[2]前記プロピレングリコール脂肪酸エステルが、プロピレングリコールと、炭素数8~18の飽和又は不飽和脂肪酸とのエステルである、上記[1]に記載の貼付製剤。
[3]前記プロピレングリコール脂肪酸エステルが、プロピレングリコールモノカプリレート又はプロピレングリコールモノラウレートである、上記[1]又は[2]に記載の貼付製剤。
[4]前記粘着剤層が、さらに、プロピレングリコール脂肪酸エステル以外の他の脂肪酸エステルを含有する、上記[1]~[3]のいずれかに記載の貼付製剤。
[5]前記他の脂肪酸エステルが、炭素数が1~18の、直鎖状若しくは分岐鎖状のアルキル基、又は環状アルキル基を有するアルコールと炭素数8~18の飽和又は不飽和脂肪酸とのエステル、及びグリセリンと炭素数が8~18の飽和又は不飽和脂肪酸とのエステルからなる群より選択される少なくとも1種である、上記[4]に記載の貼付製剤。
[6]粘着剤層100質量%中の前記プロピレングリコール脂肪酸エステルの含有量が、1~30質量%である、上記[1]~[5]のいずれかに記載の貼付製剤。
[7]レブリン酸と、プロピレングリコール脂肪酸エステルとの含有比率が、質量比で、1:0.1~1:20である、上記[1]~[6]のいずれかに記載の貼付製剤。
[8]前記粘着剤層を構成する粘着基剤が、アクリル系ポリマーである、上記[1]~[7]のいずれかに記載の貼付製剤。
[9]前記薬物が、塩基性基を有する塩基性薬物である、上記[1]~[8]のいずれかに記載の貼付製剤。
[10]前記薬物のlogPowが-1~7である、上記[1]~[9]のいずれかに記載の貼付製剤。
本発明の貼付製剤は、粘着剤層中に、薬物、レブリン酸、及びプロピレングリコール脂肪酸エステルを含有することを特徴とする。
本発明の貼付製剤における薬物は、タンドスピロン又はその薬学的に許容される塩が除かれる以外は、ヒト等の哺乳動物にその皮膚を通して投与し得る薬物(すなわち、経皮吸収可能な薬物)であれば特に限定されない。このような薬物としては、例えば、全身性麻酔薬、催眠・鎮静薬、抗癲癇薬、解熱鎮痛消炎薬、鎮暈薬、精神神経用薬、中枢神経薬、抗痴呆薬、局所麻酔薬、骨格筋弛緩薬、自律神経用薬、鎮痙薬、抗パーキンソン薬、抗ヒスタミン薬、強心薬、不整脈用薬、利尿薬、血圧降下薬、血管収縮薬、冠血管拡張薬、末梢血管拡張薬、動脈硬化用薬、循環器用薬、呼吸促進薬、鎮咳去痰薬、ホルモン薬、化膿性疾患用外用薬、鎮痛・鎮痒・収斂・消炎用薬、寄生性皮膚疾患用薬、止血用薬、痛風治療用薬、糖尿病用薬、抗悪性腫瘍用薬、抗生物質、化学療法薬、麻薬、禁煙補助薬等が挙げられる。
本発明で使用されるレブリン酸は、ケト酸に分類される有機酸である。レブリン酸は、遊離酸(すなわち、レブリン酸自体)の形態であってもよいし、その薬学的に許容される塩の形態であってもよい。薬学的に許容される塩としては、例えば、ナトリウム塩等のアルカリ金属塩等が挙げられる。レブリン酸としては、市販品をそのまま使用してもよいし、自体公知の方法に従い、レブリン酸から調製される、その薬学的に許容される塩を使用してもよい。本発明で使用されるレブリン酸としては、遊離酸であるレブリン酸が好ましい。
本発明で使用されるプロピレングリコール脂肪酸エステルとは、プロピレングリコールと、炭素数8~18の飽和又は不飽和脂肪酸とのエステルであり、例えば、プロピレングリコールモノ脂肪酸エステル、プロピレングリコールジ脂肪酸エステル等が挙げられる。プロピレングリコール脂肪酸エステルの具体例としては、例えば、プロピレングリコールモノカプリレート、プロピレングリコールモノカプレート、プロピレングリコールモノラウレート、プロピレングリコールモノステアレート、プロピレングリコールモノオレート、プロピレングリコールジカプリレート、プロピレングリコールジカプレート、プロピレングリコールジカプリレート/ジカプレート(プロピレングリコールジカプリロカプレート)、プロピレングリコールジラウレート、プロピレングリコールジステアレート、プロピレングリコールジイソステアレート、プロピレングリコールジオレート等が挙げられ、中でも、プロピレングリコールと、炭素数8~14の飽和又は不飽和脂肪酸とのエステルが好ましく、プロピレングリコールモノカプリレート又はプロピレングリコールモノラウレートがより好ましい。これらのプロピレングリコール脂肪酸エステルは、1種又は2種以上組み合わせて使用することができる。
本発明の貼付製剤においては、粘着剤層に、さらに、プロピレングリコール脂肪酸エステル以外の他の脂肪酸エステルを含むことが好ましい。このような他の脂肪酸エステルとしては、例えば、ラウリン酸エチル、ラウリン酸イソステアリル、ミリスチン酸イソプロピル、ミリスチン酸イソトリデシル、パルミチン酸イソプロピル、パルミチン酸オクチル、オレイン酸エチル等の脂肪酸アルキルエステル(炭素数が1~18の、直鎖状若しくは分岐鎖状のアルキル基、又は環状アルキル基を有するアルコールと、炭素数8~18の飽和又は不飽和脂肪酸とのエステル);モノカプリル酸グリセリル、トリカプリル酸グリセリル、トリ-2-エチルヘキサン酸グリセリル、トリカプリン酸グリセリル、トリラウリン酸グリセリル、トリイソステアリン酸グリセリル、トリオレイン酸グリセリル等のグリセリン脂肪酸エステル(グリセリンと、炭素数が8~18の飽和又は不飽和脂肪酸とのエステル)等が挙げられる。これら他の脂肪酸エステルは、1種又は2種以上組み合わせて使用することができる。
本発明の貼付製剤における粘着剤層としては、良好な皮膚接着性を発現するために、非含水系の粘着基剤を含有する粘着剤層が好ましい。このような非含水系の粘着剤層とは、完全に水分を含まないものに限定されるわけではなく、空気中の水分や皮膚等に由来する若干量の水分(例えば、粘着剤層中に1質量%未満)を含むものは包含される。
本発明の貼付製剤において、粘着剤層に適度な凝集力を付与するために、必要に応じて架橋処理を施すことができる。当該架橋処理としては、物理的架橋処理(例えば、γ線照射、電子線照射等による架橋処理)や、化学的架橋処理(例えば、有機過酸化物、イソシアネート化合物、有機金属塩、金属アルコラート、金属キレート化合物、エポキシ系化合物、第1級アミノ基含有化合物等の架橋剤による架橋処理)等が挙げられる。前記化学的架橋処理の具体例としては、例えば、過酸化ベンゾイル等の有機過酸化物、トリレンジイソシアネート、ヘキサモチレンジイソシアネート等のイソシアネート化合物、グリセリントリグリシジルエーテル、トリグリシジルイソシアヌレート等のエポキシ系化合物、アルミニウムトリス(アセチルアセトネート)、アルミニウムエチルアセトアセテートジイソプロピレート等の金属キレート化合物等の架橋剤による架橋処理が挙げられる。これらの架橋剤のうち、架橋反応性や取扱い容易性の点から、イソシアネート化合物、金属アルコラート、金属キレート化合物を用いることが好ましい。かかる架橋処理により、粘着剤層の柔軟性と凝集力等の粘着特性のバランスを好適に調整することができるため、剥離時の糊残りを抑制することができる。
本発明の貼付製剤における粘着剤層には、本発明の効果を損なわない範囲で、必要に応じて、香料、着色剤、可塑剤、軟化剤、充填剤、安定化剤、抗酸化剤、抗菌剤、殺菌剤等の各種添加剤を適宜配合してもよい。当該添加剤としては、貼付製剤の分野で公知のものを適宜選択して使用することができる。
本発明の貼付製剤を構成する支持体としては、粘着剤層を片面に形成し保持することができるものであれば、特に限定されない。支持体の材質としては、例えば、ポリエステル(例えば、ポリエチレンテレフタレート(PET)等)、ポリアミド(例えば、ナイロン等)、ポリエチレン、ポリプロピレン、ポリ塩化ビニル、ポリ塩化ビニリデン(商品名:サラン等)、アイオノマー樹脂(商品名:サーリン等)、ポリテトラフルオロエチレン、エチレン-アクリル酸エチル共重合体、エチレン-ビニルアルコール共重合体(商品名:エバール等)、各種金属等が挙げられる。支持体は、上記材質からなる各種プラスチックフィルムや各種金属箔の単層体でもよく、又はそれらの積層体でもよい。また、支持体上に形成する粘着剤層との投錨性を向上させるためには、支持体表面に下塗り層の処理、コロナ放電処理、プラズマ照射処理、プライマー処理等を行うことができる。
本発明の貼付製剤においては、粘着剤層の支持体側とは反対側の面(皮膚への貼付面)は、製剤を実際に使用するまでは、剥離ライナーが積層されているのが好ましい。当該剥離ライナーとしては、使用時に良好な剥離性を有するものできれば、特に限定されない。具体的には、粘着剤層と接触する面にシリコーン樹脂、フッ素樹脂等を塗布することによって剥離処理が施された、ポリエステル、ポリ塩化ビニル、ポリ塩化ビニリデン、ポリエチレンテレフタレート等のプラスチックフィルム、上質紙、グラシン紙等の紙、あるいは上質紙、グラシン紙等の紙とポリオレフィンとのラミネートフィルム(粘着剤層と接触する側が紙)等が挙げられる。
本発明の貼付製剤の製造方法としては、特に限定されるものではないが、例えば、以下の製造方法により製造することができる。
不活性ガス雰囲気下、アクリル酸2-エチルヘキシル55質量部、N-ビニル-2-ピロリドン40質量部、N-(2-ヒドロキシエチル)アクリルアミド5質量部、及び2,2’-アゾビスイソブチロニトリル0.2質量部を、酢酸エチル中(60℃)で溶液重合させてアクリル系ポリマー(A)の溶液を調製した。
(実施例1~2、比較例1~5)
アクリル系ポリマー(A)の溶液を、ポリエステル製剥離ライナー(厚み:75μm)の剥離処理面上に、乾燥後の厚みが100μmとなるよう塗布し、100℃、3分で乾燥して粘着剤層を形成した。形成した粘着剤層を3mmφに打ち抜いた後、表1に示す混合溶液5μLを粘着剤層へ含浸させることにより、貼付製剤を得た。貼付製剤としての各成分の含有量(質量%)は、表2に示す通りである。
ヘアレスマウスの腹部又は背部から摘出した皮膚(インタクト皮膚)の角質層面に、上記の3mmφの貼付製剤を、剥離ライナーを剥離除去した後、貼り付けた。貼付製剤を貼り付け固定した摘出皮膚を透過性試験装置に取り付け、48時間後のレセプター液をサンプリングし、超高速高分離液体クロマトグラフ(UPLC)にて、薬物の皮膚透過量を算出した。レセプター液としては、リン酸緩衝生理食塩水1Lにウシ血清由来アルブミンを40g溶解したものを使用し、温度は、32℃とした。皮膚透過性試験1の薬物の皮膚透過量の結果を表3に示す。
不活性ガス雰囲気下、アクリル酸2-エチルヘキシル72質量部、N-ビニル-2-ピロリドン25質量部、アクリル酸3質量部、及び2,2’-アゾビスイソブチロニトリル0.2質量部を、酢酸エチル中(60℃)で溶液重合させてアクリル系ポリマー(B)の溶液を調製した。
(実施例3~14、比較例6~29)
容器中に、薬物、ミリスチン酸イソプロピル(IPM)、プロピレングリコール脂肪酸エステル(PG脂肪酸エステル)、有機酸、及びアクリル系ポリマー(B)の溶液を添加して均一になるように撹拌し、アルミニウムエチルアセトアセテートジイソプロピレート(ALCH)を添加し、酢酸エチルで粘度を調整した。得られた溶液をポリエステル製剥離ライナー(厚み:75μm)の剥離処理面上に、乾燥後の厚みが100μmとなるよう塗布し、100℃、3分で乾燥して粘着剤層を形成した。
形成した粘着剤層を、厚さ2μmのポリエステル製フィルムとポリエステル製不織布(目付量:12g/m2)との積層フィルムである支持体の不織布側に貼り合わせることにより、貼付製剤を得た。貼付製剤としての各成分の含有量(質量%)は、表4、5に示す通りである。
実施例3~14、比較例6~29の貼付製剤を6mmφに打ち抜き剥離ライナーを剥離除去した後、ヘアレスマウスの腹部又は背部から摘出した皮膚(インタクト皮膚)の角質層面に、上記貼付製剤の粘着剤層面を貼り付けた。貼付製剤を貼り付け固定した摘出皮膚を透過性試験装置に取り付け、24時間後のレセプター液をサンプリングし、超高速高分離液体クロマトグラフ(UPLC)にて、薬物の皮膚透過量を算出した。レセプター液としては、リン酸緩衝生理食塩水(9.6g/L)を使用し、温度は、32℃とした。
実施例3~14、比較例6~29の貼付製剤の剥離ライナーを剥離した後、粘着剤層の露出面を指で約1秒押圧し、粘着剤層から指を離したときの粘着剤層及び指の表面の状態を下記指標で目視評価した。
〇:糸曳きはなく、指に糊残りしない
×:糸曳きが生じ、指に糊残りする
水中定荷重剥離試験について、図1を参照して説明する。
ベークライト板23(幅30mm、長さ130mm、厚さ2mm)に両面テープ(図示省略)を介してコラーゲン膜22(幅25mm、長さ100mm、厚さ38μm)を貼り合わせて試験板を準備した。次に、貼付製剤21を幅10mm、長さ40mmの矩形状に裁断し、剥離紙を剥がして粘着剤層面を露出した後、その粘着剤層面を前記試験板のコラーゲン膜22に2kgのゴムローラーで1往復して圧着貼着し、試験サンプルを得た。この状態で、室温で10分間経過した後、40℃の水24が入った水槽25中に図1に示される形状を有する支持具27を設置し、さらに、ベークライト板23の離間された2つの端部が図1に示される状態で支持具27上に載置されるように試験サンプルを設置し、貼付製剤21の一端に10gの重り26を掛け、貼付製剤21が剥がれた距離と時間を測定した。同様の試験を3回繰り返し、下記式(1)より剥離速度を算出し、その平均値をとって、これを水中定荷重剥離試験の値として算出した。この値が小さいほど、水中において剥離しにくいことを示す。
同様に、レブリン酸とPGMCとを含む貼付製剤(実施例7~8、実施例12~14)は、レブリン酸を含むがPGMCを含まない貼付製剤(比較例13、比較例24)や、PGMCを含むがレブリン酸を含まない貼付製剤(比較例14、比較例25)と比較して、皮膚透過量が高く、且つ、良好な粘着特性(凝集力、耐水接着性)を示すものであった。
なお、レブリン酸に代えて乳酸を使用した貼付製剤(比較例8~12、比較例15~17、比較例20~23、比較例26~29)は、凝集力試験において糸曳き現象が見られたことから、粘着特性の観点で使用できないものであった。
Claims (10)
- 支持体の少なくとも片面に粘着剤層を有する貼付製剤であって、
該粘着剤層が、薬物、レブリン酸、及びプロピレングリコール脂肪酸エステルを含有することを特徴とする貼付製剤。但し、薬物は、タンドスピロン又はその薬学的に許容される塩を除く。 - 前記プロピレングリコール脂肪酸エステルが、プロピレングリコールと、炭素数8~18の飽和又は不飽和脂肪酸とのエステルである、請求項1に記載の貼付製剤。
- 前記プロピレングリコール脂肪酸エステルが、プロピレングリコールモノカプリレート又はプロピレングリコールモノラウレートである、請求項1又は2に記載の貼付製剤。
- 前記粘着剤層が、さらに、プロピレングリコール脂肪酸エステル以外の他の脂肪酸エステルを含有する、請求項1~3のいずれか一項に記載の貼付製剤。
- 前記他の脂肪酸エステルが、炭素数が1~18の、直鎖状若しくは分岐鎖状のアルキル基、又は環状アルキル基を有するアルコールと炭素数8~18の飽和又は不飽和脂肪酸とのエステル、及びグリセリンと炭素数が8~18の飽和又は不飽和脂肪酸とのエステルからなる群より選択される少なくとも1種である、請求項4に記載の貼付製剤。
- 粘着剤層100質量%中の前記プロピレングリコール脂肪酸エステルの含有量が、1~30質量%である、請求項1~5のいずれか一項に記載の貼付製剤。
- レブリン酸と、プロピレングリコール脂肪酸エステルとの含有比率が、質量比で、1:0.1~1:20である、請求項1~6のいずれか一項に記載の貼付製剤。
- 前記粘着剤層を構成する粘着基剤が、アクリル系ポリマーである、請求項1~7のいずれか一項に記載の貼付製剤。
- 前記薬物が、塩基性基を有する塩基性薬物である、請求項1~8のいずれか一項に記載の貼付製剤。
- 前記薬物のlogPowが-1~7である、請求項1~9のいずれか一項に記載の貼付製剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21757414.4A EP4108237A4 (en) | 2020-02-19 | 2021-02-18 | TRANSDERMAL PATCH |
CN202180015389.5A CN115135311A (zh) | 2020-02-19 | 2021-02-18 | 贴附制剂 |
JP2022501955A JPWO2021166986A1 (ja) | 2020-02-19 | 2021-02-18 | |
CA3172786A CA3172786A1 (en) | 2020-02-19 | 2021-02-18 | Patch preparation |
US17/904,543 US20230104666A1 (en) | 2020-02-19 | 2021-02-18 | Patch preparation |
KR1020227031826A KR20220143074A (ko) | 2020-02-19 | 2021-02-18 | 패치 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-026339 | 2020-02-19 | ||
JP2020026339 | 2020-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021166986A1 true WO2021166986A1 (ja) | 2021-08-26 |
Family
ID=77392172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/006051 WO2021166986A1 (ja) | 2020-02-19 | 2021-02-18 | 貼付製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230104666A1 (ja) |
EP (1) | EP4108237A4 (ja) |
JP (1) | JPWO2021166986A1 (ja) |
KR (1) | KR20220143074A (ja) |
CN (1) | CN115135311A (ja) |
CA (1) | CA3172786A1 (ja) |
TW (1) | TW202139978A (ja) |
WO (1) | WO2021166986A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006082728A1 (ja) * | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収貼付剤 |
JP2018518502A (ja) * | 2015-06-22 | 2018-07-12 | コリウム インターナショナル, インコーポレイテッド | 難溶性治療剤を含む経皮接着性組成物 |
JP2020026339A (ja) | 2018-08-10 | 2020-02-20 | 株式会社豊田中央研究所 | 計測用カメラのキャリブレーション装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3054935B1 (en) * | 2013-10-07 | 2020-12-09 | Teikoku Pharma USA, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
-
2021
- 2021-02-18 CA CA3172786A patent/CA3172786A1/en active Pending
- 2021-02-18 CN CN202180015389.5A patent/CN115135311A/zh active Pending
- 2021-02-18 TW TW110105561A patent/TW202139978A/zh unknown
- 2021-02-18 KR KR1020227031826A patent/KR20220143074A/ko unknown
- 2021-02-18 US US17/904,543 patent/US20230104666A1/en active Pending
- 2021-02-18 WO PCT/JP2021/006051 patent/WO2021166986A1/ja unknown
- 2021-02-18 JP JP2022501955A patent/JPWO2021166986A1/ja active Pending
- 2021-02-18 EP EP21757414.4A patent/EP4108237A4/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006082728A1 (ja) * | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収貼付剤 |
JP2018518502A (ja) * | 2015-06-22 | 2018-07-12 | コリウム インターナショナル, インコーポレイテッド | 難溶性治療剤を含む経皮接着性組成物 |
JP2020026339A (ja) | 2018-08-10 | 2020-02-20 | 株式会社豊田中央研究所 | 計測用カメラのキャリブレーション装置 |
Non-Patent Citations (2)
Title |
---|
OECD GUIDELINE FOR THE TESTING OF CHEMICALS 107, 27 July 1995 (1995-07-27) |
See also references of EP4108237A4 |
Also Published As
Publication number | Publication date |
---|---|
CA3172786A1 (en) | 2021-08-26 |
JPWO2021166986A1 (ja) | 2021-08-26 |
EP4108237A4 (en) | 2024-03-06 |
KR20220143074A (ko) | 2022-10-24 |
EP4108237A1 (en) | 2022-12-28 |
TW202139978A (zh) | 2021-11-01 |
CN115135311A (zh) | 2022-09-30 |
US20230104666A1 (en) | 2023-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6193996B1 (en) | Device for the transdermal delivery of diclofenac | |
US20070098772A1 (en) | Transdermal norelgestromin delivery system | |
US20080131491A1 (en) | Percutaneously absorbable preparation | |
US20060193900A1 (en) | Pressure sensitive adhesive and patch | |
US20100010043A1 (en) | Percutaneously absorbable preparation | |
EP3251663A1 (en) | Adhesive patch | |
US7029693B2 (en) | Percutaneously absorptive preparation | |
JP2017178799A (ja) | 貼付剤 | |
JP5818709B2 (ja) | 貼付製剤 | |
JP5209433B2 (ja) | 貼付製剤 | |
JP4311728B2 (ja) | 経皮吸収型貼付剤 | |
JP3014188B2 (ja) | アクリル系ゲル材およびアクリル系ゲル製剤 | |
JP6940407B2 (ja) | フェンタニルを含む経皮薬物送達デバイス | |
WO2021166986A1 (ja) | 貼付製剤 | |
US20130287823A1 (en) | Patch | |
JPH046164B2 (ja) | ||
JPH0672879A (ja) | アスピリン含有経皮吸収製剤 | |
WO2017061393A1 (ja) | 貼付剤 | |
JP5281973B2 (ja) | ビソプロロール含有貼付剤 | |
WO2012105621A1 (ja) | 貼付製剤の製造方法 | |
JP2005281202A (ja) | 経皮吸収型貼付剤用支持体及び経皮吸収型貼付剤 | |
JPH09278650A (ja) | ニトログリセリン経皮吸収型製剤 | |
JP2008101027A (ja) | 経皮吸収型製剤 | |
JPH1149669A (ja) | 抗ウイルス剤含有テープ製剤 | |
MXPA00009361A (en) | Device for the transdermal delivery of diclofenac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21757414 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022501955 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3172786 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20227031826 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021757414 Country of ref document: EP Effective date: 20220919 |